Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CALGB 50303 trial: what clinicians have said so far
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- NCT00118209 ↗
- Completed
- Alliance for Clinical Trials in Oncology
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on CALGB 50303 (DA-EPOCH-R in untreated diffuse large B-cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CALGB 50303 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 15 posts on X | |
| 2 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Large B Cell Lymphoma
- Interventions
- rituximab; cyclophosphamide; doxorubicin; vincristine; prednisone; etoposide; filgrastim; pegfilgrastim
- Arms
- Arm A - R-CHOP · Active comparator
- Arm B - DA-EPOCH-R · Experimental
- Enrollment
- 524
- Primary outcomes
- Progression-Free Survival Rate at 2 and 5 Years
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- May 2005
- Primary completion
- Oct 2017
- Results posted
- Yes
- Registry record
- NCT00118209 · updated Nov 17, 2021
Publications
linked from the registry- Morrison VA, Le-Rademacher J, Bobek O, Satele D, Leonard JP, Jatoi A. Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303. J Geriatr Oncol. 2025 Mar;16(2):102185. doi: 10.1016/j.jgo.2025.102185. Epub 2025 Jan 13. PubMed 39809075
- Schoder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 Jun 18;135(25):2224-2234. doi: 10.1182/blood.2019003277. PubMed 32232481
- Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2. PubMed 30939090
- Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012 Aug 15;118(16):3977-83. doi: 10.1002/cncr.26723. Epub 2011 Dec 16. PubMed 22180164